Axiom Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$84.1K Buy
+1,387
New +$80.9K 0.06% 159
2022
Q4
Sell
-86
Closed -$6K 126
2022
Q3
$6K Buy
+86
New +$6.24K 0.01% 276
2022
Q1
Sell
-10,729
Closed -$668K 99
2021
Q4
$668K Sell
10,729
-9,248
-46% -$542K 0.65% 37
2021
Q3
$1.18M Buy
+19,977
New +$1.32M 1.19% 20
2021
Q1
Sell
-434
Closed -$214 197
2020
Q4
$214 Buy
+434
New +$26.7K 0.19% 109
2019
Q4
Sell
-37,197
Closed -$1.89M 148
2019
Q3
$1.89M Sell
37,197
-102,803
-73% -$4.83M 1.44% 16
2019
Q2
$6.36M Sell
140,000
-518
-0.4% -$24.1K 1.15% 17
2019
Q1
$6.73M Buy
140,518
+2,001
+1% +$99.7K 1.28% 14
2018
Q4
$7.2M Buy
+138,517
New +$7.44M 1.52% 13

Other funds holding BMY

Axiom Investment Management's BMY Position: Q1 2026 in Review

Axiom Investment Management opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 1,387 shares worth $84.1K. The stake represents 0.06% of the portfolio and ranks #159 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in BMY as recently as Q3 2022.

Axiom Investment Management first reported a position in BMY in Q4 2018 and has held it in 9 quarters since. The position peaked at $7.2M in Q4 2018. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Axiom Investment Management held 1,387 shares of Bristol-Myers Squibb worth $84.1K as of Q1 2026.
  • Bristol-Myers Squibb was a new Axiom Investment Management position in Q1 2026.
  • Bristol-Myers Squibb made up 0.06% of Axiom Investment Management's portfolio in Q1 2026, its #159 holding.
  • Axiom Investment Management first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 9 quarters since.
  • Axiom Investment Management's Bristol-Myers Squibb position peaked at $7.2M in Q4 2018.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Axiom Investment Management's 13F filing for Q1 2026, filed 26 May 2026.